| Document Date: 2015-04-22 09:44:53
Open Document File Size: 191,86 KBShare Result on Facebook
City Frimley / Basel / / Company Novartis Group / Novartis UK & Ireland / Tessa Lush Novartis Communications UK Ltd. / Novartis UK / / Country Switzerland / United Kingdom / / Currency USD / GBP / / / Event FDA Phase / / IndustryTerm generic pharmaceuticals / healthcare solutions / over-the-counter products / / MedicalCondition NYHA Class II-IV heart failure / disease / onset atrial fibrillation / fatigue / NICE heart failure / heart failure / largest heart failure / MEDIA STATEMENT Investigational heart failure / heart failure LCZ696 / ENDS- About heart failure Heart failure / / Organization Data Monitoring Committee / NHS / Medicines and Healthcare products Regulatory Agency / National Health Service / / Person Kristen Barrett / Dowd / Sarah Nixon / / / Position leader / Account Manager / Director / General Manager / / Product valsartan / LCZ696 / / URL http /
SocialTag |
MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s